2. Search Result
Search Result
Results for "

B16?F10

" in MedChemExpress (MCE) Product Catalog:

33

Inhibitors & Agonists

2

Peptides

9

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W004288
    Methyl myristate

    Tetradecanoic acid methyl ester

    		 Others Cancer
    Methyl myristate is a saturated fatty acid methyl ester obtained from the esterification of myristic acid. Methyl myristate shows a high melanin induction in B16F10 melanoma .
    Methyl myristate
  • HY-W272217
    Octacosane

    n-Octacosane; NSC 5549

    		 Endogenous Metabolite Bacterial Inflammation/Immunology Cancer
    Octacosane is an endogenous metabolite with antibacterial activity. Octacosane shows high cytotoxicity against murine melanoma B16F10-Nex2 cells besides inducing protection against a grafted subcutaneous melanoma. Octacosane has the larvicidal activity against mosquito Culex quinquefasciatus with the LC50 concentration of 7.2 mg/l .
    Octacosane
  • HY-125762
    Tyrosinase-IN-16

    		Tyrosinase Cancer
    Tyrosinase-IN-16 (compound 19a) is a tyrosine kinase (Tyrosinase) inhibitor with Ki=470 nM. Tyrosinase-IN-16 is cytotoxic to B16F10 cells, with >90% inhibition at 20 μM .
    Tyrosinase-IN-16
  • HY-N9339
    Norglaucine

    (+)-Norglaucine

    		 Others Cancer
    Norglaucine ((+)-Norglaucine), a cytotoxic alkaloid, exhibits cytotoxicity towards the tumor cell lines B16-F10, HepG2, K562 and HL-60 cells .
    Norglaucine
  • HY-162766
    Antitumor agent-184

    		Others Cancer
    Antitumor agent-184 (compound 12aa) induces cell apoptosis, with the IC50s of 2.35 μM, 7.32 μM and 10.31 μM in B16-F10 cells, 4T1 cells and CT26 cells, respectively .
    Antitumor agent-184
  • HY-155681
    SWS1

    		PD-1/PD-L1 Monoamine Oxidase Cancer
    SWS1 is a d-(+)-biotin-conjugated PD-L1 inhibitor (IC50: 1.8 nM) with anticancer activity. SWS1 can increase the number of tumor-infiltrating lymphocytes and exhibit anti-tumor efficacy in the B16-F10 mouse model (TGI=66.1%) .
    SWS1
  • HY-149950
    Anticancer agent 106

    		Apoptosis Cancer
    Anticancer agent 106 (compound 10ic) is an anticancer agent that induces apoptosis in B16-F10 melanoma cells. Anticancer agent 106 also potently inhibits metastatic nodules in a mouse model of lung metastatic melanoma. Anticancer agent 106 can be used in the study of cancer, especially lung metastatic melanoma .
    Anticancer agent 106
  • HY-N7587
    Chlorophorin

    		Melanocortin Receptor Metabolic Disease
    Chlorophorin is a inhibitor of Melanocortin Receptor. Chlorophorin reduces tyrosinase activity and inhibits a-melanocyte-stimulating hormone-induced melanin production in B16F10 melanoma cells .
    Chlorophorin
  • HY-157323
    HDAC6-IN-28

    		HDAC Apoptosis Cancer
    HDAC6-IN-28 (compound 10C) is a potent inhibitor of HDAC6 with an IC50 of 261 nM. HDAC6-IN-28 significantly induces apoptosis and S-phase arrest in B16-F10 cells. HDAC6-IN-28 efficiently increases the expression of acetylated-α-tubulin in vitro and in vivo .
    HDAC6-IN-28
  • HY-163596
    PTPN2-IN-1

    		Phosphatase Cancer
    PTPN2-IN-1 (compound 4) is a PTPN2 inhibitor with the IC50 ≤5 μM. PTPN2-IN-1 inhibits cell growth of B16F10 .
    PTPN2-IN-1
  • HY-156092
    Antitumor photosensitizer-4

    		BCRP Apoptosis Cancer
    Antitumor photosensitizer-4 (compound 10b) is a potent tyrosine kinase inhibitor (TKI) targeting ABCG2. Antitumor photosensitizer-4 is a photosensitizer (PS) consisting of a conjugate of dasatinib (HY-10181) and imatinib (HY-15463). Antitumor photosensitizer-4 induces apoptosis and ROS production and exhibits strong phototoxicity to HepG2 and B16-F10 cells .
    Antitumor photosensitizer-4
  • HY-W272217S
    Octacosane-d58

    n-Octacosane-d58; NSC 5549-d58

    		 Bacterial Endogenous Metabolite Cancer
    Octacosane-d58 is the deuterium labeled Octacosane[1]. Octacosane is an endogenous metabolite with antibacterial activity. Octacosane shows high cytotoxicity against murine melanoma B16F10-Nex2 cells besides inducing protection against a grafted subcutaneous melanoma. Octacosane has the larvicidal activity against mosquito Culex quinquefasciatus with the LC50 concentration of 7.2 mg/l[2][3][4].
    Octacosane-d58
  • HY-N3773
    Dodoviscin A

    		Tyrosinase Cancer
    Dodoviscin A is a pigmentation-altering agent, which can be isolated from the aerial parts of Dodonaea viscosa. Dodoviscin A inhibits melanin production in B16-F10 melanoma cells. Dodoviscin A suppresses mushroom tyrosinase activity, and tyrosinase activity induced by 3-isobutyl-1-methylxanthine. Dodoviscin A also inhibits the phorphosylation of cAMP response element binding protein, induced by 3-isobutyl-1-methylxanthine and forskolin .
    Dodoviscin A
  • HY-156085
    LP23

    		PD-1/PD-L1 Cancer
    LP23 is a non-arylmethylamine PD-1/PD-L1 inhibitor (IC50: 16.7 nM) with anti-tumor activity. LP23 restores immune cell function in HepG2/Jurkat T cells and promotes HepG2 cell death. LP23 is active in vivo in the B16-F10 tumor model (TGI=88.6% at 30 mg/kg) .
    LP23
  • HY-W272217R
    Octacosane (Standard)

    		Endogenous Metabolite Bacterial Inflammation/Immunology Cancer
    Octacosane (Standard) is the analytical standard of Octacosane. This product is intended for research and analytical applications. Octacosane is an endogenous metabolite with antibacterial activity. Octacosane shows high cytotoxicity against murine melanoma B16F10-Nex2 cells besides inducing protection against a grafted subcutaneous melanoma. Octacosane has the larvicidal activity against mosquito Culex quinquefasciatus with the LC50 concentration of 7.2 mg/l .
    Octacosane (Standard)
  • HY-162962
    IDO1/TDO-IN-7

    		Indoleamine 2,3-Dioxygenase (IDO) Cancer
    IDO1/TDO-IN-7 (Compound 43b), an isoquinoline derivative, is a potent dual IDO1/TDO inhibitor, with IC50s of 0.31 μM and 0.08 μM, respectively. IDO1/TDO-IN-7 displays acceptable pharmacokinetic profiles and potent antitumor efficacy with low toxicity in B16-F10 tumor model .
    IDO1/TDO-IN-7
  • HY-W004288S
    Methyl tetradecanoate-d27

    Myristic acid methyl ester-d27

    		 Isotope-Labeled Compounds Cancer
    Methyl tetradecanoate-d27 is the deuterium labeled Methyl myristate. Methyl myristate is a saturated fatty acid methyl ester obtained from the esterification of myristic acid. Methyl myristate shows a high melanin induction in B16F10 melanoma[1].
    Methyl tetradecanoate-d27
  • HY-W004288R
    Methyl myristate (Standard)

    		Others Cancer
    Methyl myristate (Standard) is the analytical standard of Methyl myristate. This product is intended for research and analytical applications. Methyl myristate is a saturated fatty acid methyl ester obtained from the esterification of myristic acid. Methyl myristate shows a high melanin induction in B16F10 melanoma .
    Methyl myristate (Standard)
  • HY-142955
    Dual photoCORM 1

    		Others Cancer
    Dual photoCORM 1 (compound 5) is metal-free, photochemically active dual CORM. Dual photoCORM 1 exhibits good cellular uptake and real-time monitoring ability of CO uncaging by a color change approach in cancerous B16F10 cells .
    Dual photoCORM 1
  • HY-160021
    RORγt agonist 4

    		ROR Inflammation/Immunology
    RORγt agonist 4 (compound 14) is a potent and selective agonist of RORγt. RORγt agonist 4 significantly enhances metabolic stability. RORγt agonist 4 improves the situation of tumor models of mouse B16F10 melanoma and LLC lung adenocarcinoma .
    RORγt agonist 4
  • HY-151509
    A2-Iso5-2DC18

    		Others Cancer
    A2-Iso5-2DC18 is a dihydroimidazole-linked lipid, served as potent mRNA delivery vehicle. A2-Iso5-2DC18 can be used for antitumor research, including B16F10 melanoma. .
    A2-Iso5-2DC18
  • HY-149523
    Anticancer agent 157

    		Apoptosis NO Synthase Caspase Inflammation/Immunology Cancer
    Anticancer agent 157 (compound 15) is a NO inhibitor (IC50=0.62 μg/mL) with anti-inflammatory and anticancer activities. Anticancer agent 157 can bind to iNOS (inducible NO synthase) and caspase 8, causing nuclear fragmentation and chromatin condensation, inducing apoptosis. Anticancer agent 157 inhibits HT29 colon cancer cells (IC50=2.45 μg/mL), Hep-G2 liver cancer cells (IC50=3.25 μg/mL), and B16-F10 murine melanoma cells (IC50=3.84 μg/mL) .
    Anticancer agent 157
  • HY-164473
    DETD-35

    		ERK Akt STAT Apoptosis Cancer
    DETD-35 is an inhibitor of the MEK-ERK, Akt, and STAT3 signaling pathways, which promotes cancer cell apoptosis (Apoptosis) and reduces cancer cell resistance to Vemurafenib (HY-12057). The IC50 values of DETD-35 against wild-type and mutant melanoma cell lines B16-F10, MeWo, SK-MEL-2, A2058c, and A375c are 2.7, 6.0, 3.9, 3.1, and 2.5 μM, respectively. DETD-35 holds promise for research in the field of anti-melanoma therapy .
    DETD-35
  • HY-P2336A
    CCZ01048 TFA

    		Melanocortin Receptor Cancer
    CCZ01048 TFA, a α-MSH analogue, exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a Ki of 0.31 nM. CCZ01048 TFA shows rapid internalization into B16F10 melanoma cells and high in vivo stability. CCZ01048 TFA is a promising candidate for PET imaging of malignant melanoma .
    CCZ01048 TFA
  • HY-P2336
    CCZ01048

    		Melanocortin Receptor Cancer
    CCZ01048, a α-melanocyte-stimulating hormone (α-MSH) analogue, exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a Ki of 0.31 nM. CCZ01048 shows rapid internalization into B16F10 melanoma cells and high in vivo stability. CCZ01048 is a promising candidate for PET imaging of malignant melanoma .
    CCZ01048
  • HY-155240
    Tyrosinase-IN-13

    		Tyrosinase Cancer
    Tyrosinase-IN-13 (compound 3c), a derivative of Flurbiprofen (HY-10582), is a potent, non-competitive tyrosinase inhibitor (IC50=68 μM; Ki=36.3 μM). Tyrosinase-IN-13 is cytotoxic against hepatocellular carcinoma (HepG2), colorectal cancer (HT-29), and melanoma (B16F10) .
    Tyrosinase-IN-13
  • HY-161971
    Tyrosinase-IN-35

    		Tyrosinase Cancer
    Tyrosinase-IN-35 (compound 6g) is a human tyrosinase inhibitor (IC50: 2.09 μM), which is more potent than Kojic Acid (HY-W050154) (IC50: 16.38 μM). Tyrosinase-IN-35 can reduce the melanin content of melanoma B16F10 cells in vitro at doses of 4 μM and 8 μM .
    Tyrosinase-IN-35
  • HY-120241
    Reticulol

    K 251-1

    		 Phosphodiesterase (PDE) Cancer
    Reticulol (K 251-1) is an inhibitor of cyclic adenosine 3', 5'-monophosphate phosphodiesterase. Reticulol shows antitumor activity independent with cell cycle arrest or apoptosis. Reticulol inhibits cell growth of murine melanoma cells and human lung tumor cells. Reticulol protects its lung metastasis via the bloodstream by inhibiting the growth of B16F10 melanoma .
    Reticulol
  • HY-156483
    TT-012

    		Others Cancer
    TT-012 specifically binds to dynamic MITF and destroys the latter's dimer formation and DNA-binding ability. TT-012 inhibits the transcriptional activity of MITF in B16F10 melanoma cells. TT-012 inhibits the growth of high-MITF melanoma cells, and inhibits the tumor growth and metastasis with tolerable toxicity to liver and immune cells in animal models .
    TT-012
  • HY-163534
    PD-1/PD-L1-IN-43

    		PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-43 (compound Z13) is a small-molecule inhibitors targeting the PD-1/PD-L1 interaction. PD-1/PD-L1-IN-43 exhibites potent in vivo antitumor efficacy against B16-F10 melanoma. PD-1/PD-L1-IN-43 inhibits tumor growth by blocking the interaction between PD-1 and PD-L1. PD-1/PD-L1-IN-43 can be used in anti-tumor studies .
    PD-1/PD-L1-IN-43
  • HY-N10802
    6-O-Isobutyrylbritannilactone

    		ERK Akt PI3K Epigenetic Reader Domain Cancer
    6-O-Isobutyrylbritannilactone is a natural melanogenesis inhibitor. 6-O-Isobutyrylbritannilactone, a sesquiterpene, can be isolated from the flowers of Inula britannica. 6-O-Isobutyrylbritannilactone inhibits IBMX (HY-12318)-induced melanin production in B16F10 cells. 6-O-Isobutyrylbritannilactone also regulates ERK, PI3K/AKT, and CREB, shows antimelanogenic activity in zebrafish embryos models .
    6-O-Isobutyrylbritannilactone
  • HY-152263
    HEMTAC CDK4/6 degrader 1

    		PROTACs CDK Apoptosis Cancer
    HEMTAC CDK4/6 degrader 1 is a PROTAC connected by ligands for HSP90 and CDK4/6 with a Kd value of 35.7 μM. HEMTAC CDK4/6 degrader 1 induces CDK4/6 degradation in B16F10 melanoma cells. HEMTAC CDK4/6 degrader 1 arrests cell cycle at G0/G1 phase and induces apoptosis. HEMTAC CDK4/6 degrader 1 can be used in research of cancer . HEMTAC CDK4/6 degrader 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    HEMTAC CDK4/6 degrader 1
  • HY-161677
    PD-L1/CD-73-IN-1

    		PD-1/PD-L1 CD73 Inflammation/Immunology Cancer
    PD-L1/CD-73-IN-1 (compound CC-5) is PD-L1/CD73 inhibitor with IC50 values of 6 nM and 0.773 μM to PD-L1 and CD73, respectively. PD-L1/CD-73-IN-1 inhibits tumor cell growth in vivo and in vitro .
    PD-L1/CD-73-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: